Laura B Creemers
Overview
Explore the profile of Laura B Creemers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
86
Citations
2054
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Elkhashab M, Barreto G, Fauconnier M, Le Bourlout Y, Creemers L, Nieminen H, et al.
Drug Deliv
. 2025 Feb;
32(1):2464921.
PMID: 39967271
Objective: Antisense oligonucleotides (ASOs) have reached the clinic; however, they lack tissue specificity. Albumin is a plasma-abundant macromolecule that has been shown to accumulate in inflamed tissues. In this work,...
2.
Wen L, Grad S, Creemers L, Stoddart M
Arthritis Res Ther
. 2025 Feb;
27(1):30.
PMID: 39934857
Background: There is a substantial need for ex vivo cartilage damage models to assess new emerging cartilage repair strategies. Ex vivo cartilage explant models have the advantages of achieving standardized...
3.
Rudnik-Jansen I, Du J, Karssemakers-Degen N, Tellegen A, Wadhwani P, Zuncheddu D, et al.
Drug Deliv
. 2024 Oct;
31(1):2415579.
PMID: 39427239
Intradiscal drug delivery is a promising strategy for treating intervertebral disk degeneration (IVDD). Local degenerative processes and intrinsically low fluid exchange are likely to influence drug retention. Understanding their connection...
4.
Muenzebrock K, Ho F, Pontes A, Jorquera-Cordero C, Utomo L, Garcia J, et al.
Pharmaceutics
. 2024 Apr;
16(4).
PMID: 38675100
Chronic lower back pain caused by intervertebral disc degeneration and osteoarthritis (OA) are highly prevalent chronic diseases. Although pain management and surgery can alleviate symptoms, no disease-modifying treatments are available....
5.
Elkhashab M, Dilek Y, Foss M, Creemers L, Howard K
Mol Pharm
. 2024 Jan;
21(2):491-500.
PMID: 38214218
Antisense nucleic acid drugs are susceptible to nuclease degradation, rapid renal clearance, and short circulatory half-life. In this work, we introduce a modular-based recombinant human albumin-oligonucleotide (rHA-cODN) biomolecular assembly that...
6.
Pontes A, van der Wal S, Roelofs K, Grobbink A, Creemers L, Engbersen J, et al.
Biomater Adv
. 2023 Dec;
156:213713.
PMID: 38071770
The successful use of mRNA vaccines enabled and accelerated the development of several new vaccine candidates and therapeutics based on the delivery of mRNA. In this study, we developed bioreducible...
7.
Pontes A, van der Wal S, Ranamalla S, Roelofs K, Tomuta I, Creemers L, et al.
Front Bioeng Biotechnol
. 2023 Nov;
11:1290871.
PMID: 38026902
Disulfide-containing poly(amidoamine) (PAA) is a cationic and bioreducible polymer, with potential use as a nanocarrier for mRNA delivery in the treatment of several diseases including osteoarthritis (OA). Successful transfection of...
8.
Ma J, Hane S, Eglauf J, Pfannkuche J, Soubrier A, Li Z, et al.
Eur Spine J
. 2023 Apr;
32(6):2048-2058.
PMID: 37071156
Purpose: This study aims to analyze the effect of pro-inflammatory cytokine-stimulated human annulus fibrosus cells (hAFCs) on the sensitization of dorsal root ganglion (DRG) cells. We further hypothesized that celecoxib...
9.
Basatvat S, Bach F, Barcellona M, Binch A, Buckley C, Bueno B, et al.
JOR Spine
. 2023 Mar;
6(1):e1238.
PMID: 36994456
Background: In vitro studies using nucleus pulposus (NP) cells are commonly used to investigate disc cell biology and pathogenesis, or to aid in the development of new therapies. However, lab-to-lab...
10.
Pontes A, Welting T, Rip J, Creemers L
Pharmaceutics
. 2022 Dec;
14(12).
PMID: 36559133
Osteoarthritis (OA) is a degenerative musculoskeletal disorder affecting the whole synovial joint and globally impacts more than one in five individuals aged 40 and over, representing a huge socioeconomic burden....